VNDA - Vanda Pharmaceuticals Inc Stock Price, Fair Value and News

5.48USD-0.10 (-1.79%)Delayed

Market Summary

USD5.48-0.10

Delayed

-1.79%

VNDA Stock Price

View Fullscreen

VNDA RSI Chart

VNDA Valuation

Market Cap

318.9M

Price/Earnings (Trailing)

-65.23

Price/Sales (Trailing)

1.8

EV/EBITDA

-65.91

Price/Free Cashflow

-27.09

VNDA Price/Sales (Trailing)

VNDA Profitability

EBT Margin

-2.17%

Return on Equity

-0.9%

Return on Assets

-0.75%

Free Cashflow Yield

-3.69%

VNDA Fundamentals

VNDA Revenue

Revenue (TTM)

177.6M

Rev. Growth (Yr)

-24.06%

Rev. Growth (Qtr)

4.84%

VNDA Earnings

Earnings (TTM)

-4.9M

Earnings Growth (Yr)

-227.49%

Earnings Growth (Qtr)

-72.75%

Breaking Down VNDA Revenue

Last 7 days

8.7%

Last 30 days

4.6%

Last 90 days

25.1%

Trailing 12 Months

-10.3%

How does VNDA drawdown profile look like?

VNDA Financial Health

Current Ratio

4.71

VNDA Investor Care

Shares Dilution (1Y)

1.31%

Diluted EPS (TTM)

-0.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	177.6M	0	0	0
2023	256.7M	238.4M	211.9M	192.6M
2022	266.2M	262.7M	257.9M	254.4M
2021	252.8M	258.5M	268.3M	268.7M
2020	237.5M	240.6M	241.4M	248.2M
2019	197.2M	208.9M	219.3M	227.2M
2018	171.3M	176.6M	184.4M	193.1M
2017	150.2M	156.2M	159.1M	165.1M
2016	121.0M	129.5M	139.6M	146.0M
2015	49.2M	75.2M	98.2M	109.9M
2014	33.3M	26.5M	23.1M	34.5M
2013	32.7M	32.6M	33.0M	33.9M
2012	31.9M	32.9M	33.2M	32.7M
2011	30.8M	29.9M	30.7M	31.3M
2010	0	14.9M	25.3M	35.7M
2009	0	0	0	4.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Vanda Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 05, 2024	birznieks gunther	sold	-35,884	4.1322	-8,684	svp, business development
Mar 05, 2024	wijkstrom joakim	sold	-38,830	4.2074	-9,229	svp, chief marketing officer
Mar 05, 2024	moran kevin patrick	sold	-37,410	4.2025	-8,902	svp, cfo & treasurer
Mar 05, 2024	williams timothy	sold	-37,395	4.1825	-8,941	svp & general counsel
Mar 05, 2024	polymeropoulos mihael hristos	sold	-100,273	4.1285	-24,288	president and ceo
Mar 04, 2024	birznieks gunther	sold	-37,494	4.2964	-8,727	svp, business development
Mar 04, 2024	wijkstrom joakim	sold	-33,090	4.4133	-7,498	svp, chief marketing officer
Mar 04, 2024	williams timothy	sold	-35,916	4.4086	-8,147	svp & general counsel
Mar 04, 2024	polymeropoulos mihael hristos	sold	-131,066	4.2438	-30,884	president and ceo
Mar 04, 2024	moran kevin patrick	sold	-25,982	4.4812	-5,798	svp, cfo & treasurer

Which funds bought or sold VNDA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	reduced	-2.42	-216	4,139	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	-15,893	23,345	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-33.59	-138,942	254,425	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	18.1	9,000	66,000	-%
May 15, 2024	Brevan Howard Capital Management LP	reduced	-28.76	-33,168	75,164	-%
May 15, 2024	Squarepoint Ops LLC	reduced	-42.22	-752,432	968,328	-%
May 15, 2024	Lido Advisors, LLC	unchanged	-	-1,103	41,203	-%
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	added	1,125	238,758	260,586	0.07%
May 15, 2024	SHERBROOKE PARK ADVISERS LLC	new	-	161,231	161,231	0.03%
May 15, 2024	Shay Capital LLC	added	78.68	55,805	131,191	0.02%

Are Funds Buying or Selling VNDA?

Are funds buying VNDA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VNDA

No. of Funds

Unveiling Vanda Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	renaissance technologies llc	6.40%	3,681,125	SC 13G/A
Feb 13, 2024	vanguard group inc	6.01%	3,456,087	SC 13G/A
Feb 09, 2024	dimensional fund advisors lp	3.4%	1,967,985	SC 13G/A
Jan 23, 2024	blackrock inc.	14.5%	8,346,367	SC 13G/A
Jan 22, 2024	state street corp	2.13%	1,228,096	SC 13G/A
Oct 06, 2023	blackrock inc.	11.8%	6,759,117	SC 13G/A
Feb 14, 2023	palo alto investors lp	1.42%	1,087,064	SC 13G/A
Feb 14, 2023	macquarie group ltd	2.34%	1,323,547	SC 13G/A
Feb 13, 2023	renaissance technologies llc	5.09%	2,889,425	SC 13G/A
Feb 10, 2023	dimensional fund advisors lp	5.0%	2,853,832	SC 13G

Recent SEC filings of Vanda Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	DEFA14A	DEFA14A
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	DEFA14A	DEFA14A
May 08, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
May 03, 2024	8-A12B/A	8-A12B/A
May 03, 2024	8-K	Current Report
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS/A	ARS/A

Peers (Alternatives to Vanda Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Vanda Pharmaceuticals Inc News

Latest updates

Vanda Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	4.8%	47.00	45.00	39.00	46.00	62.00	64.00	65.00	64.00	60.00	68.00	70.00	68.00	63.00	68.00	60.00	62.00	58.00	61.00	59.00	59.00	48.00
Costs and Expenses	8.3%	57.00	52.00	45.00	49.00	60.00	58.00	61.00	61.00	68.00	59.00	59.00	56.00	52.00	57.00	53.00	53.00	58.00	57.00	49.00	49.00	50.00
S&GA Expenses	27.4%	30.00	24.00	25.00	28.00	36.00	33.00	30.00	33.00	41.00	33.00	32.00	28.00	30.00	36.00	34.00	34.00	37.00	37.00	30.00	31.00	31.00
R&D Expenses	-13.1%	21.00	24.00	17.00	17.00	19.00	18.00	25.00	21.00	21.00	19.00	20.00	20.00	16.00	15.00	12.00	13.00	16.00	13.00	11.00	11.00	13.00
EBITDA Margin	-143.8%	-0.02*	0.04*	0.09*	0.10*	0.10*	0.05*	0.04*	0.06*	0.10*	0.16*	0.17*	0.17*	-	-	-	-	-	-	-	-	-
Income Taxes	-171.0%	-0.52	1.00	-0.30	1.00	2.00	3.00	2.00	1.00	-1.13	1.00	3.00	3.00	2.00	3.00	2.00	2.00	1.00	2.00	-88.10	0.00	0.00
Earnings Before Taxes	-180.8%	-4.66	-1.66	-0.12	3.00	6.00	10.00	5.00	4.00	-7.56	9.00	11.00	13.00	10.00	11.00	8.00	11.00	1.00	6.00	12.00	12.00	-0.60
EBT Margin	-165.9%	-0.02*	0.03*	0.08*	0.10*	0.10*	0.04*	0.04*	0.06*	0.09*	0.16*	0.17*	0.16*	-	-	-	-	-	-	-	-	-
Net Income	-72.7%	-4.15	-2.40	0.00	2.00	3.00	7.00	3.00	3.00	-6.43	7.00	8.00	10.00	9.00	8.00	6.00	9.00	0.00	4.00	100	12.00	-0.61
Net Income Margin	-311.4%	-0.03*	0.01*	0.06*	0.06*	0.06*	0.02*	0.03*	0.04*	0.07*	0.12*	0.13*	0.13*	-	-	-	-	-	-	-	-	-
Free Cashflow	289.8%	8.00	-3.98	-2.07	-13.27	32.00	9.00	13.00	5.00	4.00	26.00	9.00	19.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	0.7%	653	648	642	642	645	634	622	609	604	594	580	568	543	533	516	507	489	484	474	372	351
Current Assets	1.5%	439	433	537	534	534	519	507	497	492	478	462	447	421	409	390	381	361	354	280	316	306
Cash Equivalents	-7.5%	126	136	183	150	354	135	49.00	58.00	67.00	53.00	51.00	57.00	72.00	62.00	57.00	95.00	65.00	46.00	39.00	47.00	34.00
Inventory	10.9%	2.00	1.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Net PPE	13.2%	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
Liabilities	5.0%	109	104	99.00	102	109	107	106	101	101	89.00	86.00	86.00	76.00	80.00	75.00	75.00	72.00	73.00	74.00	76.00	73.00
Current Liabilities	6.4%	93.00	88.00	85.00	87.00	94.00	91.00	93.00	88.00	91.00	74.00	72.00	72.00	62.00	66.00	61.00	62.00	59.00	60.00	60.00	63.00	59.00
Shareholder's Equity	-0.2%	544	545	543	540	536	527	516	509	502	505	493	481	468	453	441	432	416	411	401	297	278
Retained Earnings	-2.7%	-159	-155	-152	-153	-154	-157	-164	-168	-170	-164	-171	-179	-188	-197	-205	-211	-220	-220	-224	-325	-336
Additional Paid-In Capital	0.5%	704	700	697	694	691	686	682	678	674	669	664	660	656	650	646	642	636	631	626	622	615
Shares Outstanding	1.2%	58.00	58.00	58.00	57.00	57.00	57.00	57.00	56.00	56.00	56.00	56.00	56.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	369	-	-	-	601	-	-	-	1,169	-	-	-	610	-	-	-	731	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	302.8%	7,569	-3,732	-2,050	-13,220	31,803	9,416	12,837	5,685	4,046	26,607	9,397	19,017	9,193	19,302	9,374	24,006	-907	9,791	5,998	20,515	9,643
Share Based Compensation	9.5%	3,584	3,273	3,167	3,249	4,351	3,783	3,888	3,830	4,778	3,774	3,951	3,740	3,909	3,212	3,135	3,069	3,944	3,668	3,407	3,101	3,282
Cashflow From Investing	58.4%	-18,218	-43,783	35,327	-190,894	187,294	75,428	-21,777	-14,592	10,866	-25,998	-16,588	-34,181	71.00	-16,686	-47,845	2,732	20,300	-6,230	-13,874	-11,754	-36,451
Cashflow From Financing	-	-	-	-	-	-	605	4.00	125	-	1,041	371	289	1,849	1,432	123	3,600	479	2,116	558	3,411	179

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VNDA Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Net product sales	$ 47,462	$ 62,498
Total revenues	47,462	62,498
Operating expenses:
Cost of goods sold excluding amortization	3,440	4,774
Research and development	21,154	19,237
Selling, general and administrative	30,085	36,104
Intangible asset amortization	2,018	379
Total operating expenses	56,697	60,494
Income (loss) from operations	(9,235)	2,004
Other income	4,571	3,524
Income (loss) before income taxes	(4,664)	5,528
Provision (benefit) for income taxes	(518)	2,276
Net income (loss)	$ (4,146)	$ 3,252
Net income (loss) per share:
Basic (in dollars per share)	$ (0.07)	$ 0.06
Diluted (in dollars per share)	$ (0.07)	$ 0.06
Weighted average shares outstanding:
Basic (in shares)	57,760,940	57,011,396
Diluted (in shares)	57,760,940	57,400,152

VNDA Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 125,158	$ 135,821
Marketable securities	268,984	252,443
Accounts receivable, net	36,713	34,155
Inventory	1,505	1,357
Prepaid expenses and other current assets	7,065	9,170
Total current assets	439,425	432,946
Property and equipment, net	2,306	2,037
Operating lease right-of-use assets	6,742	7,103
Intangible assets, net	119,351	121,369
Deferred tax assets	75,341	75,000
Non-current inventory and other	9,517	9,985
Total assets	652,682	648,440
Current liabilities:
Accounts payable and accrued liabilities	37,773	38,460
Product revenue allowances	55,569	49,237
Total current liabilities	93,342	87,697
Operating lease non-current liabilities	6,514	7,006
Other non-current liabilities	8,831	8,827
Total liabilities	108,687	103,530
Commitments and contingencies (Notes 9 and 14)
Stockholders’ equity:
Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized; 58,196,523 and 57,534,499 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	58	58
Additional paid-in capital	703,858	700,274
Accumulated other comprehensive loss	(383)	(30)
Accumulated deficit	(159,538)	(155,392)
Total stockholders’ equity	543,995	544,910
Total liabilities and stockholders’ equity	$ 652,682	$ 648,440

About Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

CEO	Dr. Mihael H. Polymeropoulos M.D.
WEBSITE	vandapharma.com
INDUSTRY	Biotechnology
EMPLOYEES	290

Vanda Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Vanda Pharmaceuticals Inc? What does VNDA stand for in stocks?

VNDA is the stock ticker symbol of Vanda Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vanda Pharmaceuticals Inc (VNDA)?

As of Fri May 17 2024, market cap of Vanda Pharmaceuticals Inc is 318.93 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VNDA stock?

You can check VNDA's fair value in chart for subscribers.

What is the fair value of VNDA stock?

You can check VNDA's fair value in chart for subscribers. The fair value of Vanda Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vanda Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VNDA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vanda Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether VNDA is over valued or under valued. Whether Vanda Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Vanda Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VNDA.

What is Vanda Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, VNDA's PE ratio (Price to Earnings) is -65.23 and Price to Sales (PS) ratio is 1.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VNDA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vanda Pharmaceuticals Inc's stock?

In the past 10 years, Vanda Pharmaceuticals Inc has provided -0.056 (multiply by 100 for percentage) rate of return.